INAB vs. TTOO, ORPH, ENLV, LTRN, HCWB, VCXB, IXHL, ATYR, VXRT, and CLLS
Should you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include T2 Biosystems (TTOO), Orphazyme A/S (ORPH), Enlivex Therapeutics (ENLV), Lantern Pharma (LTRN), HCW Biologics (HCWB), 10X Capital Venture Acquisition Corp. III (VCXB), Incannex Healthcare (IXHL), Atyr PHARMA (ATYR), Vaxart (VXRT), and Cellectis (CLLS). These companies are all part of the "medical" sector.
T2 Biosystems (NASDAQ:TTOO) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation.
23.2% of T2 Biosystems shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 0.1% of T2 Biosystems shares are owned by insiders. Comparatively, 15.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
IN8bio has lower revenue, but higher earnings than T2 Biosystems.
In the previous week, T2 Biosystems had 1 more articles in the media than IN8bio. MarketBeat recorded 3 mentions for T2 Biosystems and 2 mentions for IN8bio. T2 Biosystems' average media sentiment score of 1.44 beat IN8bio's score of 0.78 indicating that IN8bio is being referred to more favorably in the news media.
T2 Biosystems received 384 more outperform votes than IN8bio when rated by MarketBeat users. However, 70.97% of users gave IN8bio an outperform vote while only 64.65% of users gave T2 Biosystems an outperform vote.
T2 Biosystems has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500.
T2 Biosystems currently has a consensus price target of $3.00, suggesting a potential downside of 41.06%. IN8bio has a consensus price target of $10.00, suggesting a potential upside of 1,091.90%. Given T2 Biosystems' stronger consensus rating and higher possible upside, analysts clearly believe IN8bio is more favorable than T2 Biosystems.
IN8bio has a net margin of 0.00% compared to IN8bio's net margin of -636.09%. IN8bio's return on equity of 0.00% beat T2 Biosystems' return on equity.
Summary
IN8bio beats T2 Biosystems on 10 of the 15 factors compared between the two stocks.
Get IN8bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
